# KN035 for dMMR/MSI-H Advanced Solid Tumors

Source: https://onco.cc/trials/nct03667170/  
OnCo record `nct03667170` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Envafolimab in advanced solid tumours, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.

## Summary

KN035 for dMMR/MSI-H Advanced Solid Tumors is a phase 2 interventional study registered as NCT03667170 by 3D Medicines (Sichuan) Co., Ltd., with 200 participants planned, started 2018-08-22 and due to reach its primary completion in 2026-12-30. Interventions recorded: KN035.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03667170
- Phase: 2
- Setting: Study of KN035 as Monotherapy in Patients With Advanced Mismatched Repair Deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors
- Sponsor: 3D Medicines (Sichuan) Co., Ltd.
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT03667170: https://clinicaltrials.gov/study/NCT03667170

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Envafolimab](https://onco.cc/drugs/envafolimab/)

---
JSON: https://onco.cc/api/v1/entities/nct03667170.json